Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma

Abstract

Background: While neoadjuvant immunotherapy for melanoma has shown promising results, the data have been limited by a relatively short follow-up time, with most studies reporting 2-year outcomes. The goal of this study was to determine long-term outcomes for stage III/IV melanoma patients treated with neoadjuvant and adjuvant programmed cell death receptor 1 (PD-1) inhibition.

Patients and methods: This is a follow-up study of a previously published phase Ib clinical trial of 30 patients with resectable stage III/IV cutaneous melanoma who received one dose of 200 mg IV neoadjuvant pembrolizumab 3 weeks before surgical resection, followed by 1 year of adjuvant pembrolizumab. The primary outcomes were 5-year overall survival (OS), 5-year recurrence-free survival (RFS), and recurrence patterns.

Results: We report updated results at 5 years of follow-up with a median follow-up of 61.9 months. No deaths occurred in patients with a major pathological response (MPR, <10% viable tumor) or complete pathological response (pCR, no viable tumor) (n = 8), compared to a 5-year OS of 72.8% for the remainder of the cohort (P = 0.12). Two of eight patients with a pCR or MPR had a recurrence. Of the patients with >10% viable tumor remaining, 8 of 22 patients (36%) had a recurrence. Additionally, the median time to recurrence was 3.9 years for patients with ≤10% viable tumor and 0.6 years for patients with >10% viable tumor (P = 0.044).

Conclusions: The 5-year results from this trial represent the longest follow-up of a single-agent neoadjuvant PD-1 trial to date. Response to neoadjuvant therapy continues to be an important prognosticator with regard to OS and RFS. Additionally, recurrences in patients with pCR occur later and are salvageable, with a 5-year OS of 100%. These results demonstrate the long-term efficacy of single-agent neoadjuvant/adjuvant PD-1 blockade in patients with a pCR and the importance of long-term follow-up for these patients.

Trial registration: Clinicaltrials.gov, NCT02434354.

Keywords: follow-up studies; immunotherapy; melanoma; neoadjuvant therapy; programmed cell death 1 receptor.

Figure 1.

Overall survival. Five-year overall survival of patients with resectable stage III/IV cutaneous melanoma who received one dose of neoadjuvant pembrolizumab (200 mg) followed by surgical resection, and an additional year of adjuvant pembrolizumab stratified by (A) pathological response and (B) patterns of posttreatment tumor-infiltrating lymphocytes.

Figure 2.. Recurrence-free survival.

Five-year recurrence-free survival of patients with resectable stage III/IV cutaneous melanoma who received one dose of neo-adjuvant pembrolizumab (200 mg) followed by surgical resection, and an additional year of adjuvant pembrolizumab stratified by (A) pathological response and (B) patterns of post-treatment tumor-infiltrating lymphocytes.